Adam Schoen has over a decade of experience representing life science and medical device companies. His practice focuses on implementation of patent strategies to further business objectives and business goals. Adam’s practice is multidisciplinary, encompassing all aspects of patent preparation and prosecution, portfolio development, product clearance, freedom to operate analysis, intellectual property due diligence and licensing. Adam works with public and private companies, investors and academic institutions.

Adam has experience across the life sciences industry, working with therapeutics companies, biologics companies, diagnostic companies and medical device companies. He works with a variety of technologies, such as small molecule therapeutics, biologics (including immunotherapeutics), next generation sequencing technologies, droplet based technologies, diagnostics (including cancer and fertility diagnostics), medical device technology (ophthalmology, cardiology, orthopedics, neurology, spine), medical imaging technology (IVUS and OCT), mass spectrometry, digital health products, near field communication technology and semiconductor technology. He manages patent portfolios of all sizes and develops strategies to maximize and protect intellectual property rights in both the United States and foreign jurisdictions.

Prior to law school, Adam was a scientist of analytical chemistry for ArQule Inc., a combinatorial chemistry and drug discovery company, and a scientist at Millennium Pharmaceuticals, Inc.


New England School of Law – J.D., magna cum laude, 2006
Cornell University – B.S., 1999

Bar Admissions

Admitted, Massachusetts Bar
Registered Patent Attorney, U.S. Patent and Trademark Office
Author, "The Impact of Recent Patent Law Cases and Developments" 2016 ed., Chapter: Strategies for Using Patents to Boost a Client's Bottom Line, Aspatore Books, a Thompson Reuters business
Author, "Developing a Patent Strategy," 2015 ed., Aspatore Books, a Thompson Reuters business
The impact of Prometheus Laboratories v. Mayo Collaborative Services on medical diagnostics
The patentability of genes and isolated DNA in view of Myriad case decisions
The continued Written Description requirement for patents in view of Ariad Pharmaceuticals, Inc., v. Eli Lilly & Company
Food and Drug Administration (FDA) guidance on mobile medical applications
Speaking Engagements
Panelist, “Digital Health panel”, The Connected Health Tech-meeting, Boston, Massachusetts (October 2016)
Panelist, "Designing a Unified Patent Prosecution Strategy", The IP Strategy Summit, Boston, Massachusetts (October, 2015)
Speaker, "Effective patent strategy and pitfalls in the pharmaceutical industry", FDA boot-camp, Boston, Massachusetts (2013)